Key facts
- This page summarizes Marc Wilson's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 30 Sep 2024, 17:01.
Marc Wilson - 26 Sep 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)
- Reporting relationship
- CFO
- Issuer ticker
- CRNX
- Reported as of
- 26 Sep 2024
- Net transaction value
- -$895,500
- SEC form
- 4
- Accepted by SEC
- 30 Sep 2024, 17:01:16 UTC
- Prior SEC filing
- 26 Jul 2024
- Next SEC filing
- 29 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- Marc Wilson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Marc Wilson filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 30 Sep 2024.
Change
- Previous filing in this sequence was filed on 26 Jul 2024.
- Current net transaction value: -$895,500.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRNX
transaction
Common Stock
Options Exercise
- Transaction value
- $382,250
- Shares
- +25,000
- Change %
- +23%
- Price
- $15.29
- Shares after
- 136,092
- Date
- 26 Sep 2024
- Ownership
- Direct
CRNX
transaction
Common Stock
Sale
- Transaction value
- $1,277,750
- Shares
- -25,000
- Change %
- -18%
- Price
- $51.11
- Shares after
- 111,092
- Date
- 26 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRNX
transaction
Derivative
Stock option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -25,000
- Change %
- -22%
- Price
- $0.000000
- Shares after
- 89,000
- Date
- 26 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $15.29
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $51.11 per share. The range of sales prices on the transaction date was $50.28 to $51.54 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Footnote F3
1/48th of the shares subject to the option vested on March 26, 2021, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.